Syndax Pharmaceuticals Halted Axatilimab Development

The company stopped the drug's development for idiopathic pulmonary fibrosis following a failed Phase 2 clinical trial.

Updated on Oct. 12, 2026 in Biotech

Syndax Pharmaceuticals Halted Axatilimab Development

Live Poll

Do you believe clinical trial results are a reliable indicator for making personal investment decisions?

Syndax Pharmaceuticals has discontinued the development of axatilimab for idiopathic pulmonary fibrosis after the drug failed to meet its primary endpoint in a Phase 2 trial. Following the announcement, the company's share price dropped 13% in after-hours trading.

Why it matters

The decision follows clinical results showing the treatment did not achieve the necessary efficacy in patients. While development for this specific condition has ceased, the drug remains FDA-approved for chronic graft-versus-host disease.

The study involved 145 patients evaluated over a 26-week duration. The trial specifically measured the annualized rate of decline in forced vital capacity, which tracks the total air a patient can forcefully exhale.

The players

Syndax Pharmaceuticals

Based in New York, this biopharmaceutical company focuses on developing therapies for cancer and chronic graft-versus-host disease.

The details

The trial failed to demonstrate sufficient improvement in forced vital capacity among participants. Despite the efficacy setback, the company noted that the safety and tolerability profile of axatilimab remained consistent with data from previous studies.

October 12, 2026: The company reported a 13% drop in share price during after-hours trading.

The Tech Race

This development marks a pivot in the company's research portfolio as it manages the clinical trajectory of its lead assets. The move underscores the challenges in repurposing existing therapies for new, complex respiratory indications.

For patients currently utilizing the drug for its approved use in chronic graft-versus-host disease, this update does not affect current treatment availability. Investors should note the significant shift in the company's market valuation following the after-hours trading decline.

The takeaway

Discontinuation of clinical trials highlights the inherent risks in biopharmaceutical development even for drugs with proven efficacy in other conditions. Patients and stakeholders are encouraged to monitor ongoing updates from the company regarding its remaining clinical pipeline.